Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBD Bevacizumab Cancelled
Ibrance Palbociclib Withdrawn
Onivyde Nanoliposomal Irinotecan Cancelled
Avastin Bevacizumab Withdrawn
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Withdrawn
Venclexta Venetoclax Withdrawn
Cyramza Ramucirumab Cancelled
TBC clindamycin plus benzoyl peroxide and adapalene acne vulgaris Active
TBC daprodustat Anemia due to chronic kidney disease Withdrawn